Previous studies have reported that a higher TIL count at baseline is associated with a greater likelihood of a complete pathological response after neoadjuvant chemotherapy (NAC), particularly in human epidermal growth factor receptor-2 (HER2)-positive and triple-negative (TN; estrogen receptor [ER]/progesterone receptor [PR]/HER2-negative) breast cancers [8]. Here, ERBB2 is linked to breast carcinoma.